您的位置：首页 → 单机游戏 → 角色扮演 → 怪物猎人世界新装备介绍怪物猎人世界新装备新系统一览

春日

奥恩斯坦：切尔西曾对范戴克感兴趣，他们关注其实力而非年龄_我的网站

A | Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are weaker than it had expected and cut revenue projections by $9 billion for the year. Falling sales of both clipped sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023. Shares of Pfizer slipped more than 1% before the opening bell Monday and Moderna, which is heavily reliant on the competing vaccine it makes, slid nearly 5%. Pfizer said Friday that global usage of Paxlovid is trending slightly above last year, but that it's still below expectations.The fall vaccination period just began and the New York City drugmaker said that it's too soon to get a handle on vaccination rates for the year.Full-year revenue for Paxlovid and Comirnaty is expected to be approximately $12.5 billion, short $9 billion of what it had expected. Pfizer is lowering its full-year revenue expectations for Paxlovid by approximately $7 billion. That number also accounts for delayed commercialization of the product, which was pushed to January 2024 from the company's previous expectation of commercialization in the second half of this year. Pfizer is also lowering its 2023 revenue expectations for Comirnaty by approximately $2 billion due to lower-than-expected vaccination rates.Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion, down from its prior forecast for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1.45 and $1.65 per share due to lower-than-anticipated revenue for COVID-19-related products and inventory write-offs.That is short of the full-year revenue of $63.61 billion and earnings of $2.77 per share that Wall Street was expecting, and far short of the company's previous projections of per-share earning between $3.25 and $3.45. JPMorgan said the company's update solves an ongoing U.S. Paxlovid inventory debate and it anticipates the company's bigger-than-expected cuts to its sales projections will help put a floor under per-share earnings expectations for next year.。

在NBC体育的电视节目中，知名转会专家大卫-奥恩斯坦谈到了范戴克的情况，这位33岁的荷兰后卫最终与利物浦签订了一份为期两年的合同，结束了外界对其未来的猜测。

B |

据奥恩斯坦称，当时他的未来还未明确，切尔西是潜在的买家，尽管签下一名30多岁的高薪球员违背了切尔西目前在转会市场上瞄准年轻球员的理念。

“切尔西曾经有意签下维吉尔-范戴克，但他最终只关注利物浦。这表明斯坦福桥并没有像有些人所说的那样，只想签下23岁以下的球员。”奥恩斯坦解释道。

“是的，他们的引援很年轻化，本赛季他们的阵容平均年龄是英超联赛中最年轻的。我认为他们正在寻找有影响力的球员，无论年轻的还是年长的，而像范戴克这样的球员正是合适的人选——关键不在于他们是否年长或经验更丰富，而在于他们的实力。

Current article:http://y42y.wenwancaomohenenqiongpangshun.bond/74cax/8ns.html

Published on:12:06:52

文章评论

查看所有0条评论>>